| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Annalisa Jenkins is Director at ARDX, with reported holdings spanning 2 companies. Annalisa Jenkins's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $269K at current prices.
Annalisa Jenkins's largest disclosed position is in CMPS as Director, worth about $167K. The CMPS filings lean toward selling, a net 3,384 shares.
Annalisa Jenkins has 31 Form 4 filings on record from April 2015 to March 2026, across 6 companies: Director at Skye Bioscience (SKYE), 2024–2026; Director at Mereo BioPharma Group (MREO), 2024–2026; Director at COMPASS Pathways (CMPS), 2022–2025, and 3 more.
The 37 reported transactions were 28 option or other derivative awards, 6 tax withholdings, 2 stock awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $42K.
The only open-market sale was 3,384 shares of CMPS at an average $12.48 on March 29, 2022, about $42K. Twelve months later CMPS was down 19%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 29, 2022 | CMPS Compass Pathways Plc | Director | Sell | 3,384 | $12.48 | $42,232.32 | -14.3% | -16.8% | -19.2% |